GSK Settles $2.2B Zantac Cases, Focus Shifts to Vaccine Challenges

GSK has agreed to settle approximately 80,000 lawsuits in the U.S. related to its heartburn medication, Zantac, for up to $2.2 billion. This settlement resolves 93% of the state court cases, with a significant number in Delaware, but does not include an admission of liability by the company[1][2]. The agreement, which is anticipated to be finalized by mid-2025, follows previous settlements by Sanofi and Pfizer, addressing similar claims. Despite these financial settlements, the company has assured that its growth agenda and research and development plans remain unchanged[2].